X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES CADILA HEALTHCARE ALKEM LABORATORIES/
CADILA HEALTHCARE
 
P/E (TTM) x - 32.4 - View Chart
P/BV x 7.4 6.0 122.9% View Chart
Dividend Yield % 0.6 0.8 74.9%  

Financials

 ALKEM LABORATORIES   CADILA HEALTHCARE
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
CADILA HEALTHCARE
Mar-17
ALKEM LABORATORIES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,589460 345.4%   
Low Rs1,232305 403.9%   
Sales per share (Unadj.) Rs417.592.1 453.2%  
Earnings per share (Unadj.) Rs56.314.8 380.0%  
Cash flow per share (Unadj.) Rs64.718.5 350.2%  
Dividends per share (Unadj.) Rs12.703.20 396.9%  
Dividend yield (eoy) %0.90.8 107.6%  
Book value per share (Unadj.) Rs292.968.0 430.9%  
Shares outstanding (eoy) m119.571,023.74 11.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.2 81.4%   
Avg P/E ratio x25.125.8 97.1%  
P/CF ratio (eoy) x21.820.7 105.3%  
Price / Book Value ratio x4.85.6 85.6%  
Dividend payout %22.621.6 104.5%   
Avg Mkt Cap Rs m168,653391,581 43.1%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m9,17115,002 61.1%   
Avg. sales/employee Rs ThNM5,594.5-  
Avg. wages/employee Rs ThNM890.1-  
Avg. net profit/employee Rs ThNM899.9-  
INCOME DATA
Net Sales Rs m49,91594,295 52.9%  
Other income Rs m1,6451,286 127.9%   
Total revenues Rs m51,56195,581 53.9%   
Gross profit Rs m8,48219,036 44.6%  
Depreciation Rs m1,0063,750 26.8%   
Interest Rs m671450 149.0%   
Profit before tax Rs m8,45116,122 52.4%   
Minority Interest Rs m-114338 -33.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m1,6061,289 124.6%   
Profit after tax Rs m6,73115,168 44.4%  
Gross profit margin %17.020.2 84.2%  
Effective tax rate %19.08.0 237.7%   
Net profit margin %13.516.1 83.8%  
BALANCE SHEET DATA
Current assets Rs m27,06260,223 44.9%   
Current liabilities Rs m15,32453,058 28.9%   
Net working cap to sales %23.57.6 309.5%  
Current ratio x1.81.1 155.6%  
Inventory Days Days6770 95.2%  
Debtors Days Days4188 46.8%  
Net fixed assets Rs m12,61072,984 17.3%   
Share capital Rs m2391,024 23.3%   
"Free" reserves Rs m34,49068,576 50.3%   
Net worth Rs m35,02769,600 50.3%   
Long term debt Rs m1,21224,684 4.9%   
Total assets Rs m54,387152,207 35.7%  
Interest coverage x13.636.8 36.9%   
Debt to equity ratio x00.4 9.8%  
Sales to assets ratio x0.90.6 148.1%   
Return on assets %13.610.3 132.6%  
Return on equity %19.221.8 88.2%  
Return on capital %24.917.9 138.6%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56321,280 30.8%   
Fx outflow Rs m3,01210,874 27.7%   
Net fx Rs m3,55210,406 34.1%   
CASH FLOW
From Operations Rs m7,25913,495 53.8%  
From Investments Rs m1,864-29,103 -6.4%  
From Financial Activity Rs m-9,27323,158 -40.0%  
Net Cashflow Rs m-1507,556 -2.0%  

Share Holding

Indian Promoters % 66.9 74.8 89.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 8.3 398.8%  
FIIs % 0.0 5.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 11.0 -  
Shareholders   68,381 44,069 155.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 19, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS